gist," and that he had no way of knowing that the doctor wasn't treating adults. More generally, Johnson & Johnson's defense —as in-house litigator Joseph Braunreuther expressed — is that the drug benefits many people, which is true, and that the law governing promotion to prohibited populations, called off-label